Barclays Maintains Overweight on Ligand Pharmaceuticals, Raises Price Target to $125
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Balaji Prasad has maintained an Overweight rating on Ligand Pharmaceuticals and increased the price target from $110 to $125.
October 28, 2024 | 2:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays has reaffirmed its Overweight rating on Ligand Pharmaceuticals and increased the price target from $110 to $125, indicating a positive outlook.
The increase in price target from $110 to $125 by Barclays suggests a positive outlook for Ligand Pharmaceuticals, likely leading to a short-term increase in stock price. The Overweight rating indicates confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100